Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 51

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Endocrine ophthalmopathy

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lasn01
  • Sponsor:Lassen Therapeutics 1 Inc.

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Metabolic dysfunction-associated liver disease

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Gsk4532990A
  • Sponsor:Glaxosmithkline Research & Development Limited

Arteriosclerosis+1

Not recruiting
InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Porphyria non-acute

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate
  • Sponsor:Tanabe Pharma America Inc.

Primary hyperaldosteronism

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68Ga)
  • Sponsor:Assistance Publique Hopitaux De Paris

Type 2 diabetes mellitus+2

Not recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Testosterone Undecanoate
  • Sponsor:Medical University Of Vienna

PIK3CA related overgrowth spectrum

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Type 2 diabetes mellitus

Not recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Type 1 diabetes mellitus

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Human (Rdna)
  • Sponsor:Katholisches Klinikum Bochum gGmbH

Hypophosphatasia

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alxn1850
  • Sponsor:Alexion Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.